Purpose: The study evaluates the efficacy of cone-beam computed tomography (CBCT)-based synthetic CTs (sCT) as a potential alternative to verification CT (vCT) for enhanced treatment monitoring and early adaptation in proton therapy. Methods: Seven common treatment sites were studied. Two sets of sCT per case were generated: direct-deformed (DD) sCT and image-correction (IC) sCT. The image qualities and dosimetric impact of the sCT were compared to the same-day vCT. Results: The sCT agreed with vCT in regions of homogeneous tissues such as the brain and breast; however, notable discrepancies were observed in the thorax and abdomen. The sCT outliers existed for DD sCT when there was an anatomy change and for IC sCT in low-density regions. The target coverage exhibited less than a 5% variance in most DD and IC sCT cases when compared to vCT. The Dmaxof serial organ-at-risk (OAR) in sCT plans shows greater deviation from vCT than small-volume dose metrics (D0.1cc). The parallel OAR volumetric and mean doses remained consistent, with average deviations below 1.5%. Conclusion: The use of sCT enables precise treatment and prompt early adaptation for proton therapy. The quality assurance of sCT is mandatory in the early stage of clinical implementation.
目的:本研究评估基于锥形束计算机断层扫描(CBCT)的合成CT(sCT)作为验证CT(vCT)潜在替代方案的效能,以增强质子治疗中的治疗监测与早期适应性调整。方法:研究涵盖七个常见治疗部位。每例生成两组sCT:直接形变(DD)sCT与图像校正(IC)sCT。将sCT的图像质量与剂量学影响与同日获取的vCT进行对比分析。结果:在脑部、乳房等均匀组织区域,sCT与vCT表现一致;但在胸腹部观察到显著差异。当存在解剖结构变化时,DD sCT会出现异常值;而IC sCT在低密度区域存在偏差。与vCT相比,多数DD与IC sCT病例的靶区覆盖差异小于5%。sCT计划中串联型危及器官(OAR)的Dmax指标较vCT的偏差大于小体积剂量指标(D0.1cc)。并联型OAR的体积剂量与平均剂量保持稳定,平均偏差低于1.5%。结论:sCT的应用可实现质子治疗的精准实施与及时早期调整。在临床推广初期必须建立严格的sCT质量保证体系。